Filed with the SEC on · Summarized by InvestorsBot
Edwards Lifesciences said Corporate Vice President of Strategy and Corporate Development Donald E. Bobo Jr. plans to retire by mid-2027. The company will begin a search for his successor, with duties expected to transition during 2027; Bobo is expected to remain as a consultant through the end of 2027.
Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.
Subscribe freeEdwards Lifesciences CVP sells $2.9M in stock
Form 4 · Insider Trade · August 26, 2026
Edwards Lifesciences Raises 2026 Guidance After 13.6% Q2 Sales Growth
8-K · July 23, 2026
Edwards filed an 8‑K (Item 9.01) on Feb 10, 2026: Exhibit 99.1 is a press release reporting Q4 2025…
8-K · February 10, 2026
Edwards Lifesciences ($EW) issued a press release on Feb 10, 2026 reporting Q4 2025 financial results; the…
8-K · February 10, 2026
Edwards Lifesciences filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibit 99.1: Press Release dated Jan 9,…
8-K · January 12, 2026
Jan 9, 2026 — U.S.
8-K · January 12, 2026